IL314290A - Prevention or treatment of cardiovascular diseases with high-permeability drug inhibitors of aspirin and other NSAIDS - Google Patents

Prevention or treatment of cardiovascular diseases with high-permeability drug inhibitors of aspirin and other NSAIDS

Info

Publication number
IL314290A
IL314290A IL314290A IL31429024A IL314290A IL 314290 A IL314290 A IL 314290A IL 314290 A IL314290 A IL 314290A IL 31429024 A IL31429024 A IL 31429024A IL 314290 A IL314290 A IL 314290A
Authority
IL
Israel
Prior art keywords
nsaids
aspirin
prevention
treatment
cardiovascular diseases
Prior art date
Application number
IL314290A
Other languages
English (en)
Hebrew (he)
Original Assignee
Techfields Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Techfields Inc filed Critical Techfields Inc
Publication of IL314290A publication Critical patent/IL314290A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/625—Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL314290A 2022-01-17 2023-01-12 Prevention or treatment of cardiovascular diseases with high-permeability drug inhibitors of aspirin and other NSAIDS IL314290A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022072270 2022-01-17
PCT/CN2023/071973 WO2023134732A1 (en) 2022-01-17 2023-01-12 Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids

Publications (1)

Publication Number Publication Date
IL314290A true IL314290A (en) 2024-09-01

Family

ID=87280122

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314290A IL314290A (en) 2022-01-17 2023-01-12 Prevention or treatment of cardiovascular diseases with high-permeability drug inhibitors of aspirin and other NSAIDS

Country Status (10)

Country Link
US (1) US20250099491A1 (enExample)
EP (1) EP4465993A4 (enExample)
JP (1) JP2025504447A (enExample)
KR (1) KR20250005055A (enExample)
CN (1) CN118632699A (enExample)
AU (1) AU2023206720A1 (enExample)
CA (1) CA3252370A1 (enExample)
IL (1) IL314290A (enExample)
TW (1) TW202339711A (enExample)
WO (1) WO2023134732A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118373749A (zh) * 2024-04-29 2024-07-23 四川施成收生态科技有限公司 一种含有2-羟基苯甲酸-2-（二乙氨基）乙酯结构的化合物制备及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH399486A (fr) * 1962-10-02 1965-09-30 Biosedra Lab Procédé de préparation de nouvelles salicylamides
CA2656858C (en) * 2006-07-09 2016-01-19 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of acetylsalicylic acid
CN101500983B (zh) * 2006-07-26 2015-09-16 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性二氟尼柳及相关化合物的前药
CN111012914A (zh) * 2012-01-18 2020-04-17 苏州泰飞尔医药有限公司 治疗肺部疾病的高穿透力前药组合物和医药组合物
CN112521305B (zh) * 2013-03-15 2023-04-25 苏州泰飞尔医药有限公司 治疗帕金森疾病的新型高穿透力药物及其药物组合物

Also Published As

Publication number Publication date
JP2025504447A (ja) 2025-02-12
US20250099491A1 (en) 2025-03-27
WO2023134732A1 (en) 2023-07-20
TW202339711A (zh) 2023-10-16
EP4465993A4 (en) 2026-01-07
KR20250005055A (ko) 2025-01-09
WO2023134732A9 (en) 2024-08-08
EP4465993A1 (en) 2024-11-27
AU2023206720A1 (en) 2024-08-29
CN118632699A (zh) 2024-09-10
CA3252370A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
IL314290A (en) Prevention or treatment of cardiovascular diseases with high-permeability drug inhibitors of aspirin and other NSAIDS
IL316278A (en) TRICYCLIC PARP1 INHIBITORS AND THEIR USES
IL299870A (en) Complement factor C3 inhibitors and their medical uses
IL317930A (en) Neuromodulation of at least two neural targets in the treatment of a medical condition/underlying disease
IL312583A (en) A preparation for the treatment and prevention of COVID-19
DK4054584T3 (en) Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
IL312886A (en) Combined treatment that includes a Pegfer inhibitor and a Kras inhibitor
IL288806A (en) Stabilized mutants of "quorum quenching lactonase" and their uses in the treatment of pathogens
MX2022002413A (es) Combinaciones de inhibidores de mek con inhibidores de endonucleasas cap-dependiente.
EP4142756A4 (en) PAIN RELIEVING AND ANTI-INFLAMMATORY PREPARATION FOR THE PREVENTION AND TREATMENT OF THROMBOSIS
ZA202400388B (en) Azelaic acid esters in the treatment or prevention of dyslipidemia and associated conditions
EP4087636A4 (en) CATHETER WITH BRAID AND RADIO-OPAQUE SECTION
IL294344B1 (en) Methods for treating and/or preventing major cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor
GB202002030D0 (en) Treatment and prevention of metabolic diseases
IL325578A (en) Detection and treatment of diseases associated with C. acnes bacteria
HK40113727A (en) Methods for the prevention and treatment of synucleinopathies
GB202501605D0 (en) C-domain ACE/NEP compounds and their use in the treatment of cardiovascular diseases
GB202401411D0 (en) C-domain ACE/NEP compounds and their use in the treatment of cardiovascular diseases
IL320566A (en) Acetaminophen and naproxen for pain management
AU2020901558A0 (en) Treatment of thrombosis and associated disorders with an anti-platelet agent
AU2020901559A0 (en) Treatment of thrombosis and associated disorders with an anti-platelet agent
PT4225291T (pt) Tratamento de colangiopatias com seladelpar
GB202202291D0 (en) Apobec inhibtors and uses of the same
GB202016790D0 (en) Treatment and prevention of vascular clarification
HK40096594A (en) Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma